Gemini Therapeutics Company

Gemini Therapeutics focuses on genetically-defined dry age-related macular degeneration (AMD) and associated rare genetic diseases.
Technology: Rare Genetic Disorders
Industry: Gene Therapy
Headquarters: Cambridge, Massachusetts, United States
Founded Date: 2015
Employees Number: 11-50
Funding Status: Early Stage Venture
Investors Number: 3
Total Funding: $44.5M
Estimated Revenue: Less than $1M
Last Funding Type: Series A

Visit Website
Register and Claim Ownership